Abstract:Background: Metastasis is a major cause of death in UM, highlighting the need to use highly specific and sensitive prognostic markers to identify patients with a risk of developing metastasis. Aims: The aim of this study was to improve the current precision treatment for patients with metastatic uveal melanoma (UM). Objective: The objective of this work was to investigate the heterogeneity between primary human UM and metastatic UM at the single-cell level and to discover potential molecules regulating UM metastasis. Methods: Seurat R toolkit was employed to analyze single-cell sequencing data of UM and to identify differentially expressed genes (DEGs) between primary and metastatic UM. Least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were performed on the DEGs from the bulk RNA-seq cohort to develop a prognostic model. Based on the model, patients were divided into high and low groups. The correlations among the risk score, immune indicators, immune checkpoint blockade (ICB) therapy, and anti-tumor drug therapy were analyzed. result: Cell types in primary UM and metastatic UM tumors include B/plasma cells, endothelial cells, melanocyte, monocytes/macrophages, The photoreceptor cells and T cells. There were 157 DEGs between the two tumor types, among which S100A4, PDE4B, CHCHD10, NSG1 and C4orf48 were picked out to construct the metastasis model. The metastasis model could accurately and independently predict the risk of death and metastasis in UM, and also showed predictive usefulness for immune infiltration, response to ICB treatment, and sensitivity to antineoplastic drugs. Results: Cell types in primary UM and metastatic UM tumors include B/plasma cells, endothelial cells, melanocytes, monocytes/macrophages, photoreceptor cells, and T cells. Among 157 DEGs between the two tumor types, S100A4, PDE4B, CHCHD10, NSG1, and C4orf48 were selected to construct a prognostic model. The model could accurately and independently predict response to ICB treatment and sensitivity to antineoplastic drugs for UM patients as well as their immune infiltration levels, risk of death, and metastasis possibility. Conclusions: This study analyzed the tumor ecosystem of primary and metastatic UM, providing a metastasis-related model that could be used to evaluate the prognosis, risk of metastasis, immunotherapy, and efficacy of antineoplastic drug treatment of UM.

Single cell RNA-sequencing in uveal melanoma: advances in heterogeneity, tumor microenvironment and immunotherapy

The Prognostic Landscape of Adaptive Immune Resistance Signatures and Infiltrating Immune Cells in the Tumor Microenvironment of Uveal Melanoma.

Integration of Bulk RNA Sequencing and Single-Cell RNA Sequencing to Reveal Uveal Melanoma Tumor Heterogeneity and Cells Related to Survival

Machine learning and single-cell RNA sequencing reveal relationship between intratumor CD8+ T cells and uveal melanoma metastasis

Single-cell sequencing in primary intraocular tumors: understanding heterogeneity, the microenvironment, and drug resistance

Integrating Single-cell and Bulk RNA-seq to Construct a Metastasis-related Model for Evaluating Immunotherapy and Chemotherapy in Uveal Melanoma

Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‐cell sequencing data

Recent Advances and Challenges in Uveal Melanoma Immunotherapy

Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment

Identifying biomarkers and novel therapeutic targets in uveal melanoma

Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers

Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma

ScRNA-seq revealed the tumor microenvironment heterogeneity related to the occurrence and metastasis in upper urinary tract urothelial carcinoma

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

Uveal melanoma: Recent advances in immunotherapy

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma

Integrated single-cell and transcriptome sequencing analyses develops a metastasis-based risk score system for prognosis and immunotherapy response in uveal melanoma

A Comparative Transcriptomic Analysis Of Uveal Melanoma And Normal Uveal Melanocyte